Investor Center

EntreMed (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer and inflammatory disease using a joint US-China drug development model. EntreMed’s drug candidates target disease cells and the blood vessels that nourish them. The company’s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell signaling, cell cycle regulation and inflammation—processes that are vital to the progression of cancer and other diseases.

Investor Downloads
2012 10-K, Annual Meeting Notice and Proxy Statement
Corporate Fact Sheet
Corporate Presentation

Upcoming Events
There are no upcoming events at this time.

10-K Downloads
2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012

SEC Filings
View all SEC filings, View only Section 16 SEC filings
Please note that the above are links to www.sec.gov, a third-party web site. EntreMed, Inc. does not maintain nor provide any information directly to www.sec.gov, and therefore makes no representations or warranties regarding the the information contained therein. Further, EntreMed takes no responsibility for supplementing, updating, or correcting any information found on www.sec.gov.

XBRL Documents

View our Form 10-Q and Form 10-K filings in an interactive data format - the eXtensible Business Reporting Language (XBRL). Learn more about XBRL, or download our filings below:

2013 Form 10-K - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q3 2013 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q2 2013 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q1 2013 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

2012 Form 10-K - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q3 2012 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q2 2012 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q1 2012 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

In order to read our interactive data filings, you will need an XBRL viewer such as the viewer provided by the SEC at www.SEC.gov.

Corporate Governance Documents
Code of Ethics, Audit Committee Charter, Compensation Committee Charter, Nominating and Corporate Governance Committee Charter

Safe Harbor Information
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results may differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to our ability to obtain additional financing; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of Panzem®; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).